New drug aims to stop nosebleeds in rare genetic disorder
NCT ID NCT05406362
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called VAD044 in 75 adults with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and anemia. The first part compares two doses of VAD044 against a placebo to see if it safely reduces the number, length, and severity of nosebleeds. The second part is an open-label extension to check long-term safety and effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospices Civils de Lyon
Lyon, France
-
Hospital Universiati De Bellvitge
Barcelona, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, Spain
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Ospedale Maggiore di Crema
Crema, Italy
-
St. Antonius Hospital
Nieuwegein, Netherlands
-
Universitair Ziekenhuis Gent
Ghent, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New ointment could tame HHT nosebleeds
- New drug aims to stop nosebleeds in rare blood vessel disorder
- Can a cancer drug tame rare bleeding Disorder's heart complications?
- HHT drug trial pulled before it even started
- HHT nosebleed drug shows promise in long-term follow-up study
- New study reveals how HHT symptoms impact daily life